Search results
The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer
Zacks via Yahoo Finance· 2 years agoFor Immediate Release Chicago, IL – May 31, 2022 – Zacks.com announces the list of stocks featured...
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
Zacks via Yahoo Finance· 4 months agoThis week, Pfizer PFE issued a disappointing guidance for 2024, which includes its expectations from...
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoWe expect investors to focus on the sales performance of Novavax’s NVAX protein-based COVID-19...
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III
Zacks via Yahoo Finance· 9 months agoThis week, AstraZeneca AZN, Sanofi SNY and AbbVie ABBV and Roche announced second-quarter earnings....
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
Zacks via Yahoo Finance· 7 months agoThe FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo...
Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo
Zacks via Yahoo Finance· 1 year agoThis week, the FDA approved Sanofi’s SNY Altuviiio, a new class of factor VIII therapy for...
Pharma Stock Roundup: J&J New Buyback Plan, CHMP Nod to PFE's BA.4, BA.5 Omicron Jab
Zacks via Yahoo Finance· 2 years agoThis week, J&J JNJ announced plans to buy back $5 billion worth of shares and reaffirmed its profit...
Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine
Zacks via Yahoo Finance· 1 year agoThis week, AstraZeneca AZN and Sanofi’s SNY RSV vaccine, nirsevimab and Sanofi and GSK’s GSK...
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
Zacks via Yahoo Finance· 2 years agoModerna, Inc. MRNA reported earnings of $5.24 per share for the second quarter of 2022, beating the...
Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why
Zacks via Yahoo Finance· 2 years agoValneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance...